Targeted Treatment for Differentiated Thyroid Cancer

Lova Sun, MD, discusses genetic alterations in thyroid cancer, including RET and NTRK alterations, and how these can affect treatment options.

Lova Sun, MD, discusses the importance of identifying genetic alterations in thyroid cancer, including RET and NTRK alterations.

Lova Sun, MD, MSCE, discusses targeted therapies for NTRK and RET alterations in thyroid cancers.

Lova Sun, MD, MSCE, discusses resistance mechanisms against targeted agents for the treatment of thyroid cancer.

Lova Sun, MD, MCSE, assistant professor at the Hospital of the University of Pennsylvania, discusses the important of next-generation sequencing for patients with thyroid cancer.

Lori J. Wirth, MD, discusses the background and design of the phase 3 SELECT trial of lenvatinib vs placebo for the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer.